DUBLIN, Nov. 25, 2014 /PRNewswire/ -- Jazz
Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company
will be webcasting its corporate presentations at two upcoming
investor conferences.
- 31st NASDAQ Investor Program in
London, UK on Tuesday, December 2, 2014 at 6:45 a.m. EST / 11:45 a.m.
GMT. Iain McGill, senior vice
president and head of EUSA International, will provide an overview
of the company and a business and financial update.
- 26th Annual Piper Jaffray
Healthcare Conference in New York,
NY on Tuesday, December 2,
2014 at 2:00 p.m. EST /
7:00 p.m. GMT. Bruce Cozadd, chairman and chief executive
officer, will provide an overview of the company and a business and
financial update.
A live audio webcast of each presentation may be accessed from
the Investors section of the Jazz Pharmaceuticals website at
www.jazzpharmaceuticals.com. Please connect to the website prior to
the start of the presentation to ensure adequate time for any
software downloads that may be necessary to listen to the
webcast.
An archive of the webcast will be available for at least one
week following the presentation on the Investors section of the
company's website at www.jazzpharmaceuticals.com.
About Jazz Pharmaceuticals plc
Jazz Pharmaceuticals
plc (Nasdaq: JAZZ) is a specialty biopharmaceutical company focused
on improving patients' lives by identifying, developing and
commercializing differentiated products that address unmet medical
needs. The company has a diverse portfolio of products and/or
product candidates in the areas of sleep, hematology/oncology, pain
and psychiatry. The company's U.S. marketed products in these areas
include: Xyrem® (sodium oxybate) oral solution, Erwinaze®
(asparaginase Erwinia chrysanthemi), Prialt® (ziconotide)
intrathecal infusion, Versacloz® (clozapine) oral suspension,
FazaClo® (clozapine, USP) HD and FazaClo LD. Jazz Pharmaceuticals
also has a number of products marketed outside the United States, including Erwinase® and
Defitelio® (defibrotide). For more information, please visit
www.jazzpharmaceuticals.com.